Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
The Company granted stock options to purchase up to an aggregate of
9,500 shares of
About
Kala is a biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary AMPPLIFYTM
mucus-penetrating particle (MPP) Drug Delivery Technology, with an
initial focus on the treatment of eye diseases. Kala has applied the
AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol
etabonate (LE), designed for ocular applications, resulting in recently
approved INVELTYSTM for the treatment of inflammation and
pain following ocular surgery and its lead product candidate, KPI-121
0.25%, for the temporary relief of the signs and symptoms of dry eye
disease, for which a New Drug Application (NDA) has been filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190222005022/en/
Source:
Investor Contact:
Michael Schaffzin, 212-362-1200
michael@sternir.com
or
Media
Contact:
Kari Watson, 781-235-3060
kwatson@macbiocom.com